GlassScriptPhysician profile
Ata T Salek
NPI 1063567840
$10,617.59
in general payments reported to CMS, 2019-2025
47 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $1,330 · 2021: $1,766 · 2022: $1,830 · 2023: $1,677 · 2024: $1,379 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,638.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,090.57 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,080.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $801.84 | 2021-2025 | |
| Amgen INC. | $629.14 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $555.02 | 2019-2020 | |
| Abbvie INC. | $526.19 | 2019-2024 | Linzess, Viberzi, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.37 | 2019-2025 | Jardiance |
| Pfizer INC. | $490.08 | 2019-2024 | |
| Lilly USA, LLC | $409.37 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $324.01 | 2019-2023 | Steglujan, Steglatro |
| Exact Sciences Corporation | $311.62 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $262.62 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.05 | 2020-2024 | Xifaxan |
| Abbott Laboratories | $186.49 | 2021-2024 | Freestyle Libre 3, Eterna |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ata Salek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.